DelMar Pharmaceuticals, Inc. (DMPI) Expected to Announce Earnings of -$0.17 Per Share
Equities research analysts predict that DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) will report earnings of ($0.17) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for DelMar Pharmaceuticals’ earnings. DelMar Pharmaceuticals reported earnings of ($0.23) per share in the same quarter last year, which would indicate a positive year over year growth rate of 26.1%. The firm is expected to issue its next quarterly earnings results on Thursday, November 9th.
On average, analysts expect that DelMar Pharmaceuticals will report full-year earnings of ($0.61) per share for the current year, with EPS estimates ranging from ($0.65) to ($0.57). For the next year, analysts anticipate that the business will post earnings of ($0.26) per share. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for DelMar Pharmaceuticals.
DMPI has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of DelMar Pharmaceuticals in a report on Thursday, October 5th. Maxim Group reaffirmed a “hold” rating on shares of DelMar Pharmaceuticals in a report on Monday, September 11th. Finally, Dawson James reaffirmed a “buy” rating on shares of DelMar Pharmaceuticals in a report on Tuesday, August 8th.
Shares of DelMar Pharmaceuticals (DMPI) traded down 1.8184% during midday trading on Friday, hitting $0.8639. The company’s stock had a trading volume of 369,232 shares. The firm’s market cap is $18.62 million. DelMar Pharmaceuticals has a 52-week low of $0.80 and a 52-week high of $5.70. The stock’s 50 day moving average is $1.01 and its 200-day moving average is $1.92.
An institutional investor recently bought a new position in DelMar Pharmaceuticals stock. Franklin Resources Inc. bought a new position in DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,076,923 shares of the company’s stock, valued at approximately $2,477,000. 8.64% of the stock is currently owned by institutional investors.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.